Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial

Non-small-cell lung cancer (NSCLC) represents the predominant form (85  %-90 %) of malignant lung neoplasms [1]. In 2020, lung cancer accounted for 2,206,771 new cases globally, leading to 1,796,144 fatalities [2,3]. At the dawn of the 21st century, chemotherapy remained the cornerstone of NSCLC treatment. However, the emergence of immunotherapy has introduced a pl ethora of innovative strategies for NSCLC management [4,5]. Currently, platinum-based chemotherapy, either alone or in combination with immunotherapy, is the endorsed first-line treatment paradigm for NSCLC [1,6,7].

Source: Lung Cancer - March 18, 2024 Category: Cancer & Oncology Authors: Xingxiang Pu, Zemin Xiao, Jia Li, Zhijun Wu, Zhongxia Ma, Jie Weng, Maoliang Xiao, Yanhua Chen, Yongqing Cao, Peiguo Cao, Qianzhi Wang, Yan Xu, Kang Li, Bolin Chen, Fang Xu, Liyu Liu, Yi Kong, Hui Zhang, Huaxin Duan, Lin Wu Tags: Research Paper Source Type: research